213 related articles for article (PubMed ID: 23714544)
1. Genomic landscape of squamous cell carcinoma of the lung.
Morgensztern D; Devarakonda S; Govindan R
Am Soc Clin Oncol Educ Book; 2013; ():348-53. PubMed ID: 23714544
[TBL] [Abstract][Full Text] [Related]
2. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition.
Goodwin J; Neugent ML; Lee SY; Choe JH; Choi H; Jenkins DMR; Ruthenborg RJ; Robinson MW; Jeong JY; Wake M; Abe H; Takeda N; Endo H; Inoue M; Xuan Z; Yoo H; Chen M; Ahn JM; Minna JD; Helke KL; Singh PK; Shackelford DB; Kim JW
Nat Commun; 2017 May; 8():15503. PubMed ID: 28548087
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive genomic characterization of squamous cell lung cancers.
Cancer Genome Atlas Research Network
Nature; 2012 Sep; 489(7417):519-25. PubMed ID: 22960745
[TBL] [Abstract][Full Text] [Related]
4. Personalized therapy on the horizon for squamous cell carcinoma of the lung.
Kim HS; Mitsudomi T; Soo RA; Cho BC
Lung Cancer; 2013 Jun; 80(3):249-55. PubMed ID: 23489560
[TBL] [Abstract][Full Text] [Related]
5. Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma.
Devarakonda S; Morgensztern D; Govindan R
Oncology (Williston Park); 2013 Sep; 27(9):899-906. PubMed ID: 24282988
[TBL] [Abstract][Full Text] [Related]
6. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.
Campbell JD; Alexandrov A; Kim J; Wala J; Berger AH; Pedamallu CS; Shukla SA; Guo G; Brooks AN; Murray BA; Imielinski M; Hu X; Ling S; Akbani R; Rosenberg M; Cibulskis C; Ramachandran A; Collisson EA; Kwiatkowski DJ; Lawrence MS; Weinstein JN; Verhaak RG; Wu CJ; Hammerman PS; Cherniack AD; Getz G; ; Artyomov MN; Schreiber R; Govindan R; Meyerson M
Nat Genet; 2016 Jun; 48(6):607-16. PubMed ID: 27158780
[TBL] [Abstract][Full Text] [Related]
7. New developments in the treatment of squamous cell lung cancer.
Filipits M
Curr Opin Oncol; 2014 Mar; 26(2):152-8. PubMed ID: 24441504
[TBL] [Abstract][Full Text] [Related]
8. Expression and roles of lumican in lung adenocarcinoma and squamous cell carcinoma.
Matsuda Y; Yamamoto T; Kudo M; Kawahara K; Kawamoto M; Nakajima Y; Koizumi K; Nakazawa N; Ishiwata T; Naito Z
Int J Oncol; 2008 Dec; 33(6):1177-85. PubMed ID: 19020750
[TBL] [Abstract][Full Text] [Related]
9. Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma.
Staaf J; Isaksson S; Karlsson A; Jönsson M; Johansson L; Jönsson P; Botling J; Micke P; Baldetorp B; Planck M
Int J Cancer; 2013 May; 132(9):2020-31. PubMed ID: 23023297
[TBL] [Abstract][Full Text] [Related]
10. Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma.
Lockwood WW; Chari R; Coe BP; Thu KL; Garnis C; Malloff CA; Campbell J; Williams AC; Hwang D; Zhu CQ; Buys TP; Yee J; English JC; Macaulay C; Tsao MS; Gazdar AF; Minna JD; Lam S; Lam WL
PLoS Med; 2010 Jul; 7(7):e1000315. PubMed ID: 20668658
[TBL] [Abstract][Full Text] [Related]
11. Genetic alterations defining NSCLC subtypes and their therapeutic implications.
Pikor LA; Ramnarine VR; Lam S; Lam WL
Lung Cancer; 2013 Nov; 82(2):179-89. PubMed ID: 24011633
[TBL] [Abstract][Full Text] [Related]
12. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
[TBL] [Abstract][Full Text] [Related]
13. Genomics of squamous cell lung cancer.
Rooney M; Devarakonda S; Govindan R
Oncologist; 2013 Jun; 18(6):707-16. PubMed ID: 23728941
[TBL] [Abstract][Full Text] [Related]
14. Identification of differentially expressed genes between lung adenocarcinoma and lung squamous cell carcinoma by gene expression profiling.
Lu C; Chen H; Shan Z; Yang L
Mol Med Rep; 2016 Aug; 14(2):1483-90. PubMed ID: 27356570
[TBL] [Abstract][Full Text] [Related]
15. Genomic alterations in lung adenocarcinoma.
Devarakonda S; Morgensztern D; Govindan R
Lancet Oncol; 2015 Jul; 16(7):e342-51. PubMed ID: 26149886
[TBL] [Abstract][Full Text] [Related]
16. Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma.
Vallejo-Díaz J; Olazabal-Morán M; Cariaga-Martínez AE; Pajares MJ; Flores JM; Pio R; Montuenga LM; Carrera AC
Oncotarget; 2016 Dec; 7(51):85063-85078. PubMed ID: 27835880
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical profiling of ALK fusion gene-positive adenocarcinomas of the lung.
Sakai Y; Nakai T; Ohbayashi C; Imagawa N; Yanagita E; Satake R; Nitta A; Kajimoto K; Sakuma T; Itoh T
Int J Surg Pathol; 2013 Oct; 21(5):476-82. PubMed ID: 23794492
[TBL] [Abstract][Full Text] [Related]
18. New insights into the molecular profile of lung adenocarcinoma and implications for therapy.
Ganesh B; Devarakonda S; Govindan R
Expert Rev Anticancer Ther; 2015 Apr; 15(4):361-4. PubMed ID: 25745793
[TBL] [Abstract][Full Text] [Related]
19. Novel therapies for advanced squamous cell carcinoma of the lung.
Koutsoukos K; Mountzios G
Future Oncol; 2016 Mar; 12(5):659-67. PubMed ID: 26880383
[TBL] [Abstract][Full Text] [Related]
20. A decade of advances in treatment for advanced non-small cell lung cancer.
Gettinger S; Lynch T
Clin Chest Med; 2011 Dec; 32(4):839-51. PubMed ID: 22054890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]